Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_assertion type Assertion NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_head.
- NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_assertion wasGeneratedBy ECO_0000203 NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_provenance.
- NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_assertion wasDerivedFrom befree-20150227 NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_provenance.
- NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_assertion SIO_000772 23760401 NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_provenance.
- NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_assertion evidence source_evidence_literature NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_provenance.
- NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_assertion description "[Taken together, our findings support the hypotheses that CD44 and CAM-DR contribute to lenalidomide resistance in multiple myeloma, that CD44 should be evaluated as a putative biomarker of sensitivity to lenalidomide, and that ATRA or other approaches that target CD44 may overcome clinical lenalidomide resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP279426.RAAhDVfzuRuSY0KwW6g9tuzgw_rYseQYC19Xz8cGpMlwE130_provenance.